A possible link of gut microbiota alteration in type 2 diabetes and Alzheimer's disease pathogenicity: An update

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 383-390

  Alam, Mohammad Z ^a   Alam, Qamre ^a   Kamal, Mohammad A ^a   Abuzenadah, Adel M ^a   Haque, Absarul ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alzheimer's disease; Inflammation; Insulin resistance; Macrobiotic; Obesity; Tall like receptor; Type 2 diabetes

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; APOPTOSIS; CALORIC INTAKE; DIETARY INTAKE; ENERGY EXPENDITURE; HUMAN; INFLAMMATION; INSULIN RELEASE; INTESTINE FLORA; METABOLIC ACTIVITY ASSAY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENICITY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GASTROINTESTINAL TRACT; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY;

ALZHEIMER DISEASE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; MICROBIOTA; OBESITY;

EID: 84904459295     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660151     Document Type: Review

References (80)

1. Larsen N, Vogensen FK, van den Berg FWJ, et al. Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults. PLoS ONE 2010; 5(2): e9085.
2. Tilg H, Moschen AR, Kaser A. Obesity and the microbiota. Gastroenterology 2009; 136(5): 1476-83.
3. Duncan SH, Lobley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes 2008; 32 (11): 1720-4.
4. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361(9356): 512-9.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-28.
6. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008; 51: 1781-9.
7. Cani PD, Possemiers S, Wiele TVD, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58(8): 1091-103.
8. Membrez M, Blancher F, Jaquet M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22(7): 2416-26.
9. Ley RE, Bäckhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102(31): 11070-5.
10. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457(7228): 480-4.
11. Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr Diab Rep 2004; 4(4): 237-46.
12. Gasparini L, Gouras GK, Wang R, et al. Stimulation of betaamyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21(8): 2561-70.
13. Savage DC. Microbial ecology of the gastrointestinal tract. Ann Rev Microbiol 1977; 31: 107-33.
14. Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001; 108(4): 516-20.
15. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7(7): 688-93.
16. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464(7285): 59-65.
17. Stephen AM, Cummings JH. The microbial contribution to human faecal mass. J Med Microbiol 1980; 13(1): 45-56.
18. Sears CL. A dynamic partnership: celebrating our gut flora. Anaerobe 2005; 11(5): 247-51.
19. Steinhoff U. Who controls the crowd? New findings and old questions about the intestinal microflora. Immunol Lett 2005; 99(1): 12-6.
20. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 2002; 16(6): 915-31.
21. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489(7415): 220-30.
22. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009; 106(7): 2365-70.
23. Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 1974; 27(5): 961-79.
24. Suau A, Bonnet R, Sutren M, et al. Direct Analysis of Genes Encoding 16S rRNA from Complex Communities Reveals Many Novel Molecular Species within the Human Gut. Appl Env Microbiol 1999; 65(11): 4799-807.
25. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the Human Intestinal Microbial Flora Sci 2005; 308(5728): 1635-8.
26. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473(7346): 174-80.
27. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334(6052): 105-8.
28. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57(6): 1470-81.
29. Santacruz A, Marcos A, Wärnberg J, et al. Interplay Between Weight Loss and Gut Microbiota Composition in Overweight Adolescents. Obesity 2009; 17(10): 1906-15.
30. Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring Bacterial Community of Human Gut Microbiota Reveals an Increase in Lactobacillus in Obese Patients and Methanogens in Anorexic Patients. PLoS ONE 2009; 4(9): e7125.
31. Beaugerie L, Petit JC. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol 2004; 18(2): 337-52.
32. Gibson GR. Fibre and effects on probiotics(the prebiotic concept). Clin Nut Suppl 2004; 1(2): 25-31.
33. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101(44): 15718-23.
34. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104(3): 979-84.
35. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3(4): 213-23.
36. Fleissner CK, Huebel N, Abd El-Bary MM, et al. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 2010; 104(6): 919-29.
37. Lin HV, Frassetto A, Kowalik EJ Jr, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PloS ONE 2012; 7(4): e35240.
38. Samuel BS, Gordon JI. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci USA 2006; 103(26): 10011-6.
39. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444(7122): 1022-3.
40. Murphy EF, Cotter PD, Healy S, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010; 59(12): 1635-42.
41. Parks BW, Nam E, Org E, et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab 2013; 17(1): 141-52.
42. Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292(2): G518-25.
43. Sun L, Yu Z, Ye X, et al. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 2010; 33(9): 1925-32.
44. Amar J, Burcelin R, Ruidavets JB, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87(5): 1219-23.
45. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56(7): 1761-72.
46. Boroni Moreira AP, de Cássia Gonçalves Alfenas R. The influence of endotoxemia on the molecular mechanisms of insulin resistance. Nutr Hosp 2012; 27(2): 382-90.
47. Griffiths EA, Duffy LC, Schanbacher FL, et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci 2004; 49(4): 579-89.
48. Ruan X, Shi H, Xia G, et al. Encapsulated Bifidobacteria reduced bacterial translocation in rats following hemorrhagic shock and resuscitation. Nutrition 2007; 23(10): 754-61.
49. Wang Z, Xiao G, Yao Y, et al. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma 2006; 61(3): 650-7.
50. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118(2): 229-41.
51. Poggi M, Bastelica D, Gual P, et al. C3H/HeJ mice carrying a tolllike receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007; 50(6): 1267-76.
52. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006; 346(3): 739-45.
53. Vice E, Privette JD, Hickner RC, Barakat HA. Ketone body metabolism in lean and obese women. Metab Clin Exp 2005; 54(11): 1542-5.
54. Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000; 47(3): 397-403.
55. Vinolo MAR, Rodrigues HG, Hatanaka E, et al. Short-chain fatty acids stimulate the migration of neutrophils to inflammatory sites. Clin Sci 2009; 117(9): 331-8.
56. Mahowald MA, Rey FE, Seedorf H, et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci USA 2009; 106(14): 5859-64.
57. Gao Z, Yin J, Zhang J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58(7): 1509-17.
58. Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol 2009; 24(6): 943-54.
59. Craft S. Insulin resistance syndrome and Alzheimer's disease: Ageand obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005; 26(1 Suppl): 65-9.
60. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286(3): 327-34.
61. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21(3): 383-421.
62. Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased Interleukin(IL)-1β Messenger Ribonucleic Acid Expression in β - Cells of Individuals with Type 2 Diabetes and Regulation of IL-1β in Human Islets by Glucose and Autostimulation. J Clin Endocrinol Metab 2008; 93(10): 4065-74.
63. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117(14):3720-32.
64. Ehses JA, Ellingsgaard H, Böni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. Arch Physiol Biochem 2009; 115(4): 240-7.
65. Chellan P, Nagaraj RH. Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch Biochem Biophys 1999; 368(1): 98-104.
66. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
67. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46(8): 2916-24.
68. Zhu Y, Shu T, Lin Y, et al. Inhibition of the receptor for advanced glycation endproducts(RAGE) protects pancreatic β-cells. Biochem Biophys Res Commun 2011; 404(1): 159-65.
69. Dasu MR, Devaraj S, Park S, Jialal I. Increased Toll-Like Receptor(TLR) Activation and TLR Ligands in Recently Diagnosed Type 2 Diabetic Subjects. Diabetes Care 2010; 33(4): 861-8.
70. Jialal I, Huet BA, Kaur H, Chien A, Devaraj S. Increased Toll-Like Receptor Activity in Patients With Metabolic Syndrome. Diabetes Care 2012; 35(4): 900-4.
71. Barton GM, Medzhitov R. Toll-Like Receptor Signaling Pathways. Science 2003; 300(5625): 1524-5.
72. Schulthess FT, Paroni F, Sauter NS, et al. CXCL10 Impairs β Cell Function and Viability in Diabetes through TLR4 Signaling. Cell Metab 2009; 9(2): 125-39.
73. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11(2): 155-61.
74. Gautam S, Banerjee M. The macrophage Ox-LDL receptor, CD36 and its association with type II diabetes mellitus. Mol Genet Metab 2011; 102(4): 389-98.
75. Kennedy DJ, Kashyap SR. Pathogenic Role of Scavenger Receptor CD36 in the Metabolic Syndrome and Diabetes. Metab Syndr Relat Disord 2011; 9(4): 239-45.
76. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991; 12(4): 295-312.
77. Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and betaamyloid in normal adults. Arch Neurol 2005; 62(10): 1539-44.
78. Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63(7): 1187-92.
79. Montine TJ, Kaye JA, Montine KS, et al. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 2001; 125(4): 510-2.
80. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009; 42(8): 475-81.